Oseltamivir use and outcomes during the 2009 influenza A H1N1 pandemic in Taiwan

BMC Public Health

Volumn 13, Issue 1, 2013, Pages

  Liu, Chia Hung ^a,b   Wang, Jiun Ling ^c   Su, Chia Ping ^d   Chuang, Jen Hsiang ^d   Chang, Chia Hsuin ^a,e   Lai, Mei Shu ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c I SHOU UNIVERSITY   (Taiwan)

^d CENTER FOR DISEASE CONTROL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

H1N1 subtype; Influenza A virus; Mortality; Oseltamivir; Pandemic

Indexed keywords

ANTIVIRUS AGENT; OSELTAMIVIR;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COHORT ANALYSIS; DRUG EFFECT; ECONOMICS; FACTUAL DATABASE; FEMALE; HUMAN; INFLUENZA; INFLUENZA VIRUS A H1N1; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; PRESCRIPTION; PUBLIC HEALTH; STATISTICS; TAIWAN; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; COHORT STUDIES; DATABASES, FACTUAL; DRUG PRESCRIPTIONS; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; OSELTAMIVIR; TAIWAN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84879998282     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-13-646     Document Type: Article

References (26)

1. World Health organization, Pandemic (H1N1) 2009-update 112 Weekly update 2010 Available at: http://www.who.int/csr/don/2010-08-06/en/index.html. (Accessed Dec 11 2012)
2. European Centre for Disease Prevention and Control, Guide to public health measures to reduce the impact of influenza pandemics in Europe: "The ECDC Menu" Available at: http://www.ecdc.europa.eu/ (Accessed Dec 11,2012)
3. World Health organization, WHO guidelines for pharmacological management of pandemic Influenza A(H1N1) 2009 and other Influenza Viruses Available at: http://www.who.int/csr/resources/publications/swineflu/h1n1-use-antivirals- 20090820/en/ (Accessed Dec 11 2012)
4. Uyeki TM; Centers for Disease Control and Prevention (CDC): antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP). Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, MMWR Recomm Rep 2011 60 1 24 22108587
5. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Jefferson T, Jones MA, Doshi P, Del Mar CB, Heneghan CJ, Hama R, Thompson MJ, Cochrane Database Syst Rev 2012 1 CD008965
6. Neuraminidase inhibitors-the story behind the Cochrane review. Doshi P, BMJ 2009 339 5164 10.1136/bmj.b5164 19995813
7. Patterns in influenza antiviral medication use before and during the 2009 H1N1 pandemic, vaccine safety data link project, 2000-2010. Greene SK, Shay DK, Yin R, McCarthy NL, Baxter R, Jackson ML, Jacobsen SJ, Nordin JD, Irving SA, Naleway AL, Glanz JM, Lieu TA, Influenza Other Respi Viruses. 2012 6 143 51 10.1111/j.1750-2659.2012.00390.x 22687171
8. Nationwide surveillance of influenza during the pandemic (2009-10) and post-pandemic (2010-11) periods in Taiwan. Chuang JH, Huang AS, Huang WT, Liu MT, Chou JH, Chang FY, Chiu WT, PLoS One 2012 7 36120 10.1371/journal.pone. 0036120 22545158
9. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, Uyeki TM, Zaki SR, Hayden FG, Hui DS, Kettner JD, Kumar A, Lim M, Shindo N, Penn C, Nicholson KG, Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza, N Engl J Med 2010 362 1708 1719 20445182
10. US antiviral resistance surveillance working group: oseltamivir-resistant pandemic (H1N1) 2009 virus infections, United States, 2010-11. Storms AD, Gubareva LV, Su S, Wheeling JT, Okomo-Adhiambo M, Pan CY, Reisdorf E, St George K, Myers R, Wotton JT, Robinson S, Leader B, Thompson M, Shannon M, Klimov A, Fry AM, Emerg Infect Dis. 2012 18 308 311 10.3201/eid1802.111466 22305467
11. Early findings of oseltamivir-resistant pandemic (H1N1) 2009 influenza A viruses in Taiwan. Yang JR, Huang YP, Lin YC, Su CH, Kuo CY, Hsu LC, Wu HS, Liu MT, Antiviral Res 2010 88 256 262 10.1016/j.antiviral.2010.09.014 20869989
12. Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010/11. Lackenby A, Moran Gilad J, Pebody R, Miah S, Calatayud L, Bolotin S, Vipond I, Muir P, Guiver M, McMenamin J, Reynolds A, Moore C, Gunson R, Thompson C, Galiano M, Bermingham A, Ellis J, Zambon M, Euro Surveill 2011 16 19784 21315056
13. Seroprevalence and severity of 2009 pandemic influenza A H1N1 in Taiwan. Chen CJ, Lee PI, Chang SC, Huang YC, Chiu CH, Hsieh YC, Chang SC, Chang FY, Lee JJ, Su SC, Shen GH, Chuang YC, Chen YS, Liu JW, Lin TY, PLoS One 2011 6 24440 10.1371/journal.pone.0024440 21909433
14. Age distribution of cases of 2009 (H1N1) pandemic influenza in comparison with seasonal influenza. Karageorgopoulos DE, Vouloumanou EK, Korbila IP, Kapaskelis A, Falagas ME, PLoS ONE 2011 6 21690 10.1371/journal.pone.0021690 21747947
15. Description of antiviral treatment among adults hospitalized with influenza before and during the 2009 pandemic: United States, 2005-2009. Doshi S, Kamimoto L, Finelli L, Perez A, Reingold A, Gershman K, Yousey-Hindes K, Arnold K, Ryan P, Lynfield R, Morin C, Baumbach J, Hancock EB, Bennett NM, Zansky S, Thomas A, Schaffner W, Fry AM, J Infect Dis 2011 204 1848 1856 10.1093/infdis/jir648 22013219
16. Detection of 2009 pandemic influenza A(H1N1) virus infection in different age groups by using rapid influenza diagnostic tests. Gao F, Loring C, Laviolette M, Bolton D, Daly ER, Bean C, Influenza Other Respi Viruses 2012 6 30 34 10.1111/j.1750-2659.2011.00313.x 22114876
17. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. Van Kerkhove MD, Vandemaele KA, Shinde V, Jaramillo-Gutierrez G, Koukounari A, Donnelly CA, Carlino LO, Owen R, Paterson B, Pelletier L, Vachon J, Gonzalez C, Hongjie Y, Zijian F, Chuang SK, Au A, Buda S, Krause G, Haas W, Bonmarin I, Taniguichi K, Nakajima K, Shobayashi T, Takayama Y, Sunagawa T, Heraud JM, Orelle A, Palacios E, van der Sande MA, Wielders CC, Hunt D, Cutter J, Lee VJ, Thomas J, Santa-Olalla P, Sierra-Moros MJ, Hanshaoworakul W, Ungchusak K, Pebody R, Jain S, Mounts AW, WHO Working Group for Risk Factors for Severe H1N1pdm Infection, PLoS Med 2011 8 1001053 10.1371/journal.pmed.1001053 21750667
18. Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis. Burch J, Corbett M, Stock C, Nicholson K, Elliot AJ, Duffy S, Westwood M, Palmer S, Stewart L, Lancet Infect Dis 2009 9 537 545 10.1016/S1473-3099(09)70199-9 19665930
19. Antiviral agents: to treat or not to treat? An old dilemma revisited in light of new data from the 2009 influenza A(H1N1) pandemic. Hernandez JM, Lopez-Rodas V, Costas E, J Clin Virol 2010 49 145 146 10.1016/j.jcv.2010.07.001 20674477
20. Monitoring and characterization of oseltamivir-resistant pandemic (H1N1) 2009 virus, Japan, 2009-2010. Ujike M, Ejima M, Anraku A, Shimabukuro K, Obuchi M, Kishida N, Hong X, Takashita E, Fujisaki S, Yamashita K, Horikawa H, Kato Y, Oguchi A, Fujita N, Tashiro M, Odagiri T, Influenza Virus Surveillance Group of Japan, Emerg Infect Dis 2011 17 470 479 10.3201/eid1703.101188 21392439
21. Norwegian Institute of Public Health, Norwegian Prescription Database (NorPD) at the Norwegian Institute of Public Health Available at: http://www.norpd.no/ (Accessed Dec 11,2012)
22. Estimating effect of antiviral drug use during pandemic (H1N1) 2009 outbreak, United States. Atkins CY, Patel A, Taylor TH Jr, Biggerstaff M, Merlin TL, Dulin SM, Erickson BA, Borse RH, Hunkler R, Meltzer MI, Emerg Infect Dis 2011 17 1591 1598 10.3201/eid1709.110295 21888783
23. Influenza A(H1N1)pdm09 in England, 2009 to 2011: a greater burden of severe illness in the year after the pandemic than in the pandemic year. Mytton OT, Rutter PD, Donaldson LJ, Euro Surveill 2012 17 20139 22516004
24. National Institute for Health Data and Disease Control, Medicine sales in Denmark Copenhagen,Denmark: Statens Serum Instituts Available at: http://www.medstat.dk/en. (Accessed Dec 11,2012)
25. The European Centre for Disease Prevention and Control (ECDC), Daily Update 2009 influenza A(H1N1) pandemic, 28 December 2009, 14.00 CEST (Reported number of cumulative confirmed fatal 2009 pandemic influenza A(H1N1) cases in EU and EFTA countries, as 28 December 2009, 14.00 CEST, and in the rest of the world by country, as of 31 December 2009, 14.00 CEST 2009
26. acterial coinfections in lung tissue specimens from fatal cases of 2009 pandemic influenza A (H1N1)-United States, May-August 2009. Centers for Disease Control and Prevention (CDC), MMWR Morb Mortal Wkly Rep 2009 58 1071 1074 19798021